Centralized Entry Review Pilot Terminated by FDA
The Food and Drug Administration terminated its centralized entry review pilot program effective at 10:30 p.m. on Sept. 30. This pilot was launched Aug. 12 and was to have run through Nov. 2 but the FDA decided to end it early due to the Oct. 1 lapse in federal appropriations.
Under this pilot, entry documents requested by the FDA were submitted via the Import Trade Auxiliary Communication System. The pilot was conducted at the following ports of entry that primarily serve as courier hubs.
- FedEx in Memphis (2095), Oakland (2895), Anchorage (3195), Newark (4671) and Miami (5297)
- DHL Worldwide Express in Riverside (2792), Detroit (2870) and Miami (5296)
- UPS in Ontario, Calif. (2795), Anchorage (3196), Newark (4670) and Miami (5295)
- Los Angeles (2791)
- IBC in Miami (5298)
Due to the termination of the pilot, FDA entry review coverage for these ports of entry has reverted to the previous offices. The FDA advises that importers and/or entry filers who file through the above ports should direct communications to the FDA district covering the port of entry for the entry.